A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)()()()

BACKGROUND: Pembrolizumab shows robust antitumor activity and favorable safety in metastatic melanoma. KEYNOTE-151 evaluated pembrolizumab in Chinese patients, who have more aggressive melanoma subtypes than other populations. METHODS: Chinese patients aged ≥18 years with advanced melanoma previousl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Oncol
Main Authors: Si, Lu, Zhang, Xiaoshi, Shu, Yongqian, Pan, Hongming, Wu, Di, Liu, Jiwei, Lou, Fang, Mao, Lili, Wang, Xuan, Wen, Xizhi, Gu, Yanhong, Zhu, Lingjun, Lan, Shijie, Cai, Xin, Diede, Scott J., Zhou, Yu, Ge, Jun, Li, Jianfeng, Wu, Haiyan, Guo, Jun
Formato: Artigo
Idioma:Inglês
Publicado em: Neoplasia Press 2019
Assuntos:
Original article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6458446/
https://ncbi.nlm.nih.gov/pubmed/30981094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2019.02.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados